Lambda, the GPU cloud company founded by AI engineers and powered by NVIDIA GPUs, today announced that Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, has selected Lambda Cloud to provide NVIDIA H100 Tensor Core GPUs to accelerate training and inference for its leading generative AI drug discovery models.
“As we work to continuously search chemical space for potential molecules that may one day treat disease, there is a need for immense amounts of reliable computing power to support our current models and enable Iambic to continuously innovate. Lambda was able to create a custom cluster to meet our compute needs, provide key engineering expertise, and has demonstrated an ability to rapidly scale to meet our near-term requirements,” said Matt Welborn, Iambic’s Director of Machine Learning.
Iambic’s generative AI drug discovery models include NeuralPLexer, a state-of-the-art model for predicting protein-ligand structures, including conformation changes resulting from drug interactions. Predictions from NeuralPLexer and Iambic’s suite of models are served to Iambic’s integrated AI and high throughput experimental chemistry and biology labs, where thousands of unique molecules are synthesized and assayed every week.
“At Lambda, we’re committed to solving difficult compute challenges for customers across industries. Enabling transformer models in drug discovery efforts is an important step toward unlocking AI’s potential for advancing therapeutics,” said Stephen Balaban, Lambda CEO and co-founder. “We’re thrilled to collaborate with Iambic as they discover new medicines and look forward to working with more companies reimagining their endeavors through powerful AI and GPU compute access.”
Iambic joins leading global companies and research institutions like Anyscale, Sony, Rakuten, The AI Institute, and more in adopting Lambda Cloud. Lambda, an early provider of NVIDIA H100 GPUs, serves thousands of customers across manufacturing, healthcare, pharmaceuticals, financial services, and the U.S. government. Lambda’s high-speed interconnect allows for training and fine-tuning of AI models on a cloud built for AI workloads - delivering a fast, cost-efficient, and easy-to-use GPU cloud for engineers achieving breakthrough innovations and enabling the next generation of tech.
Click here to learn more about Lambda’s cloud offerings for AI training and inference.
About Lambda
Lambda was founded in 2012 by AI engineers with published research at the top machine learning conferences in the world. Our goal is to become the #1 AI compute platform serving developers across the entire AI development lifecycle. We enable AI engineers to easily, securely and affordably build, test and deploy AI products at scale. Our product portfolio spans from on-prem GPU hardware to hosted GPUs in the cloud. Lambda’s mission is to create a world where access to computation is as effortless and ubiquitous as electricity.
About Iambic Therapeutics
Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514390873/en/
